Sudarshan Pharma Industries has reported a remarkable turnaround in its financial performance for the first quarter, showcasing significant improvements across key metrics.

Financial Highlights

• Net Profit: ₹37.00 crore, compared to a loss of ₹12.00 crore in Q1 last year
• Revenue: Grew to ₹140.00 crore from ₹100.00 crore year-over-year
• EBITDA: Surged to ₹10.30 crore from ₹2.00 crore
• EBITDA Margin: Expanded to 7.22% from 1.94%

Strong Revenue Growth

Sudarshan Pharma Industries demonstrated robust revenue growth, with its top line increasing by 40% year-over-year to reach ₹140.00 crore. This substantial growth indicates a significant expansion in the company's market presence and sales performance.

Profitability Turnaround

The most notable aspect of Sudarshan Pharma's Q1 results is the impressive turnaround in profitability. The company swung from a loss of ₹12.00 crore in the same quarter last year to a net profit of ₹37.00 crore, marking a substantial improvement in its bottom line.

EBITDA Performance

The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) showed a remarkable improvement, increasing more than fivefold from ₹2.00 crore to ₹10.30 crore. This significant boost in EBITDA reflects enhanced operational efficiency and cost management.

Margin Expansion

Sudarshan Pharma Industries' EBITDA margin expanded considerably, rising from 1.94% in the previous year to 7.22% in the current quarter. This margin expansion of 528 basis points underscores the company's ability to improve its operational efficiency and profitability.

The strong financial performance across all key metrics indicates that Sudarshan Pharma Industries has successfully implemented strategies to drive growth and improve profitability. The company's ability to turn around its operations and deliver substantial improvements in revenue, EBITDA, and net profit positions it well for future growth in the pharmaceutical sector.

Sudarshan Pharma Industries Limited has made a strategic move to strengthen its presence in the Middle East by acquiring Cibachem General Trading LLC, a Dubai-based company, as a wholly-owned subsidiary. Simultaneously, the company announced the resignation of its Chief Financial Officer, marking significant changes in both its international operations and internal management.

Acquisition of Cibachem General Trading LLC

Sudarshan Pharma has completed the acquisition of 300 shares of Cibachem General Trading LLC for Rs. 55.00 lakh, representing 100% of Cibachem's paid-up share capital. The shares were purchased from three existing shareholders:

1. Mr. Nilesh Harish Thakkar - 225 shares (75%)
2. Mrs. Hina Harish Thakkar - 54 shares (18%)
3. Mr. Benjamin Harish Thakkar - 21 shares (7%)

Cibachem, established in 2013, is registered with the Department of Economic Development of the Emirate of Dubai under commercial license no. 696207. The company operates in the general trading business, which includes carrying on activities related or ancillary to trading, except for insurance, banking, or investment of funds for third parties.

Financial Performance of Cibachem

Cibachem's financial performance over the past three years shows a stable revenue stream:

Strategic Implications

The acquisition is expected to help Sudarshan Pharma enlarge its customer base in the Middle East region. This move aligns with the company's expansion strategy and could potentially open up new market opportunities in the Gulf region.

Management Change

In a separate development, Sudarshan Pharma announced that Mr. Manoj Lodha has resigned from his position as Chief Financial Officer, effective August 5, 2025. The company disclosed this information in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance

The acquisition of Cibachem required approval from the Reserve Bank of India under the Foreign Exchange Management Act, 1999, and related rules and regulations. The company has confirmed that all necessary approvals have been obtained under the automatic route.

Sudarshan Pharma Industries Limited continues to demonstrate its commitment to growth and expansion in international markets. The acquisition of Cibachem General Trading LLC marks a significant step in the company's strategy to strengthen its foothold in the Middle East, while the management change signals ongoing developments in its corporate structure.